Podcasts about clinical science

In this episode of Around the School Table, produced by Xuno, host Steve Davis is joined by Dr. Gina Biancarosa, Ann Swindells Chair in Education, Professor in the Department of Special Education and Clinical Sciences, and Director of the Center on Teaching and Learning at the University of Oregon (uoregon.edu), to explore the origins, purpose, and growing impact of DIBELS (Dynamic Indicators of Basic Early Literacy Skills) in schools across Australia and beyond. Throughout the conversation, Gina explains how DIBELS was developed to help educators identify students who may need additional support with reading. Rather than relying solely on lengthy assessments, DIBELS uses brief, targeted measures that provide valuable insights into a student's literacy development. As a result, teachers can monitor progress more frequently and make informed instructional decisions. The discussion explores the science behind key DIBELS assessments, including letter naming fluency, phonemic awareness, nonsense word fluency, oral reading fluency, and comprehension measures. Furthermore, Gina explains how each assessment aligns with the research on how children learn to read and develop reading comprehension over time. Steve and Gina also examine the importance of reading for meaning. While decoding words is essential, comprehension remains the ultimate goal. Consequently, the episode highlights why effective literacy instruction must support both accurate word recognition and deep understanding of text. In addition, listeners will learn how Australian educators have embraced DIBELS through professional learning communities, including the highly active DIBELS in Oz network. Gina reflects on the collaborative efforts that led to the development of an Australasian version of DIBELS, ensuring greater relevance for Australian and New Zealand students. The conversation also explores how literacy data can be used responsibly within broader school improvement strategies. While assessment data can guide intervention and goal-setting, Gina emphasises the importance of using DIBELS for its intended purpose rather than as a blunt accountability tool. The discussion also touches on how DIBELS data can be analysed and interpreted within broader school improvement processes using tools such as Student Maps. Beyond assessment, Gina shares her personal reflections on reading as a lifelong gift. From childhood favourites to supporting readers with vision impairment, she highlights the profound opportunities that literacy creates throughout life. This episode offers valuable insights for teachers, school leaders, literacy specialists, and education professionals seeking practical ways to support reading growth while maintaining a strong focus on student understanding and success. Powered by: xuno.com.auSee omnystudio.com/listener for privacy information.

In this episode of Around the School Table, produced by Xuno, host Steve Davis is joined by Dr. Gina Biancarosa, Ann Swindells Chair in Education, Professor in the Department of Special Education and Clinical Sciences, and Director of the Center on Teaching and Learning at the University of Oregon (uoregon.edu), to explore the origins, purpose, and growing impact of DIBELS (Dynamic Indicators of Basic Early Literacy Skills) in schools across Australia and beyond. Throughout the conversation, Gina explains how DIBELS was developed to help educators identify students who may need additional support with reading. Rather than relying solely on lengthy assessments, DIBELS uses brief, targeted measures that provide valuable insights into a student's literacy development. As a result, teachers can monitor progress more frequently and make informed instructional decisions. The discussion explores the science behind key DIBELS assessments, including letter naming fluency, phonemic awareness, nonsense word fluency, oral reading fluency, and comprehension measures. Furthermore, Gina explains how each assessment aligns with the research on how children learn to read and develop reading comprehension over time. Steve and Gina also examine the importance of reading for meaning. While decoding words is essential, comprehension remains the ultimate goal. Consequently, the episode highlights why effective literacy instruction must support both accurate word recognition and deep understanding of text. In addition, listeners will learn how Australian educators have embraced DIBELS through professional learning communities, including the highly active DIBELS in Oz network. Gina reflects on the collaborative efforts that led to the development of an Australasian version of DIBELS, ensuring greater relevance for Australian and New Zealand students. The conversation also explores how literacy data can be used responsibly within broader school improvement strategies. While assessment data can guide intervention and goal-setting, Gina emphasises the importance of using DIBELS for its intended purpose rather than as a blunt accountability tool. The discussion also touches on how DIBELS data can be analysed and interpreted within broader school improvement processes using tools such as Student Maps. Beyond assessment, Gina shares her personal reflections on reading as a lifelong gift. From childhood favourites to supporting readers with vision impairment, she highlights the profound opportunities that literacy creates throughout life. This episode offers valuable insights for teachers, school leaders, literacy specialists, and education professionals seeking practical ways to support reading growth while maintaining a strong focus on student understanding and success. Powered by: xuno.com.auSee omnystudio.com/listener for privacy information.

In this episode, Annika Theodoulou speaks to Dr Vera Buss, a Senior Research Fellow at University College London, and Professor Leonie Brose, a Professor of Addictions & Public Health at King's College London, UK. The interview covers Vera and Leonie's research article examining the association between the national ‘Swap to Stop' programme offering free vapes for smoking cessation and quit attempts in England.Background on the Swap to Stop program in England [01:10]The motivations behind the study [01:50]The Smoking Toolkit Study and using an Interrupted Time Series Analysis [03:00]The key findings of the study [04:50]The factors which Vera and Leonie adjusted for [07:00]The policy landscape in England regarding vaping as a smoking cessation aid [07:41]What can other countries learn from the findings [09:12]The surprising results of this study [09:50]The implications of the findings for policy and practice [10:36]About Annika Theodoulou: Annika is a Research Fellow at the National Centre for Education and Training on Addiction at Flinders University, South Australia. Her work focuses on health behaviours, including smoking cessation and weight management, with an emphasis on evidence synthesis. She completed a Doctor of Philosophy in Primary Health Care at the University of Oxford, where her research examined socioeconomic inequalities in smoking cessation behaviours and outcomes using quantitative and qualitative methods. Her doctoral research was funded by the Society for the Study of Addiction and The Rotary Foundation. Annika is an Associate Editor of Nicotine & Tobacco Research and holds a Bachelor of Health Sciences and a Master of Clinical Science from the University of Adelaide.About Vera Buss: Vera is a Senior Research Fellow in Behavioural Science at the UCL Tobacco and Alcohol Research Group and part of the Behavioural Research UK consortium. Her research focuses on understanding and monitoring tobacco smoking and alcohol consumption across Great Britain, drawing on the Smoking and Alcohol Toolkit Studies to evaluate national policies and population‑level behaviour change. Alongside her research, Vera co‑leads undergraduate and postgraduate teaching on health psychology and statistics for public health.About Leonie Brose: Leonie is Professor of Addictions & Public Health at King's College London and Director of the National Institutes for Health and Care Research (NIHR) Policy Research Unit in Addictions. Most of Leonie's research has focused on tobacco control, smoking cessation, smoking and mental health and newer nicotine products and she has co-authored six government-commissioned reviews on vaping. Leonie is active in the Society for the Study of Addiction, the Society for Research on Nicotine and Tobacco and its European chapter. She also contributes as an Editorial Board member for Addiction and Nicotine & Tobacco Research and as Programme Lead for the MSc Addictions at King's. Leonie is an Associate Editor for Addiction and a Trustee for the SSA.Original article: Associations between the national ‘Swap to Stop' programme offering free vapes for smoking cessation and quit attempts in England: Results from a population-based survey https://doi.org/10.1111/add.70332The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.Music by Jack Shakespeare Hosted on Acast. See acast.com/privacy for more information.

With Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia, Sotiria Liori, National & Kapodistrian University of Athens Medical School, Athens - Greece, Sarah Birkhoelzer, University Dorset Hospital, Bournemouth - UK, Joseph Selvanayagam, Flinders University, Adelaide - Australia, Sam Straw, University of Leeds, Leeds - UK, Ida Arentz Taraldsen, Copenhagen University Hospital, Copenhagen - Denmark, Fabian Kerwagen,  University Hospital of Wurzburg, Wurzburg - Germany, Dirk Van Veldhuisen and Kevin Damman, University Medical Centre Groningen, Groningen - The Netherlands. In this episode, we discuss the late-breaking clinical science presented at the Heart Failure Congress 2026 in Barcelona, Spain. First, Sarah Birkhoelzer interviews Joseph Selvanayagam, who presents the results of RESOLVE-HCM, a trial evaluating perhexiline for regression of left ventricular hypertrophy in symptomatic hypertrophic cardiomyopathy. Next, Sam Straw interviews Ida Arentz Taraldsen, who highlights the key findings of REDOX-AHF, a trial comparing restrictive versus liberal oxygenation targets in patients with acute heart failure and pulmonary congestion. Finally, Fabian Kerwagen interviews Dirk Van Veldhuisen and Kevin Damman, who discuss the DECISION trial and the accompanying meta-analysis. DECISION evaluated low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction, while the meta-analysis assessed the efficacy and safety of digitalis glycosides across contemporary heart failure trials. This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

Sehlomola Mashatole – Founder & Group CEO, MashUbora SAfm Market Update - Podcasts and live stream

In today's VETgirl online veterinary continuing education podcast, Drs. Andy Moorhead, Associate Professor, Department of Clinical Sciences at North Carolina State University and Uri Donnett, Chief Veterinarian, Dane County Humane Society in Madison, Wisconsin discuss the why, when and how of activity restriction during heartworm treatment. There's more to canine heartworm treatment than administering medications to eliminate adult heartworms. Activity restriction of patients during treatment is a factor that's critical to treatment success, BUT facilitating this kind of lifestyle change—even though temporary—can be challenging for both veterinarians and clients.Sponsored By: American Heartworm Society

In this episode, Dr Annika Theodoulou speaks to Dr James Buszkiewicz, a Research Assistant Professor and social epidemiologist at the University of Michigan, United States. The interview covers James's research article covering the associations between county-level e-cigarette-inclusive Tobacco 21 law population coverage and e-cigarette use behaviors among United States adolescents.Tobacco 21 laws and e-cigarette-inclusive Tobacco 21 laws [01:29]The importance of exploring e-cigarette-inclusive T21 laws and e-cigarette use behaviors [03:30]The use of the Monitoring the Future Study [04:25]The key findings of the study [06:34]The expectations and surprising findings from the study [09:02]The implications of the findings internationally [10:54]About Annika Theodoulou: Annika is a researcher at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. Her work focuses on health behaviours, including smoking cessation and weight management, with an emphasis on evidence synthesis. Annika's doctoral research, funded by the Society for the Study of Addiction (SSA) and The Rotary Foundation, examined socioeconomic inequalities in smoking cessation behaviours and outcomes using quantitative and qualitative methods. She is an Associate Editor of Nicotine & Tobacco Research. Annika holds a Bachelor of Health Sciences and a Master of Clinical Science from the University of Adelaide.About James Buszkiewicz: James is a Research Assistant Professor and social epidemiologist at the University of Michigan School of Public Health. He applies epidemiologic and econometric methods to study how policies can address structural determinants of health. His research has explored the effects of state minimum wage laws, the built environment, economic shocks from the COVID-19 pandemic, and local, state, and federal tobacco control policies on cardiometabolic health, diet, food insecurity, and tobacco use. A key motivation in his work is a desire to reduce racial, ethnic, and socioeconomic health disparities through data-driven policy change.Original article: Associations between county-level e-cigarette-inclusive Tobacco 21 law population coverage and e-cigarette use behaviors among United States adolescents in Monitoring the Future https://doi.org/10.1111/add.70266 The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.Music by Jack Shakespeare. Hosted on Acast. See acast.com/privacy for more information.

Transcript Paper: Gearhardt AN, Brownell KD, Brandt AM. From Tobacco to Ultraprocessed Food: How Industry Engineering Fuels the Epidemic of Preventable Disease. Milbank Q. 2026;104(1):0202.https://doi.org/10.1111/1468-0009.70066 https://www.milbank.org/quarterly/articles/from-tobacco-to-ultraprocessed-food-how-industry-engineering-fuels-the-epidemic-of-preventable-disease/ Ashley, let's talk a little bit about, just set the stage for what this paper was all about, and since it was your brainchild, you approached Allan and me about being involved. Tell us what you set out to do and why you thought these issues were worth digging into. Ashley - You know, I've just been so struck that when we think of cigarettes, they were something that's so common, so normal that we kind of think, oh, they've always just sort of been there. But truly, they're just taking a natural plant from the ground and through advancements and corporate engineering and technology and knowhow, they took a poisonous plant and made it into the most deadly and addictive drug in human history. And yet that was, you know, just accompanied by tons of debate. It didn't look like other addictive substances. And I just really felt like, man, we're reliving this history right now when it comes to how we've altered our food supply. I wanted to really bring you all together and see if we could really lay that story out of the, the parallels of these two public health crises. We'll get in a minute into the issue of what you discovered, but tell us what you covered, what the paper was meant to do. Ashley - The paper really goes back from how you take the tobacco plant in the field, or the corn in the field, and walks essentially through all the kind of levers that are being pulled to transform it in very specific ways. And through specific technologies and corporate practices that are being shared by modern cigarettes and ultra processed foods. These products maybe look harmless on their face initially, or don't look like they're just maybe pleasurable or craveable. But truly, I would argue that they've crossed thresholds into things that are addictive and clearly damaging many people's lives. Okay, so several decades ago, I don't know who came up with a term, but there was a lot of discussion about similarities between tobacco industry behavior and food industry behavior. And the press started publishing cover pieces that would say food is the next tobacco. And it was a term that the food industry really didn't like, and they don't want that comparison at all. It'll be interesting to see whether they deserve it. You clearly made that connection in this paper. Allan, let's turn to you. Oh my God. I mean, we could do a 15-hour podcast and not cover the history of the tobacco industry. There's so much to say, enough that you wrote a massive book about it. But give an overall sense, if you will, of the kind of tactics and morality of that industry. Allan - Well, as Ashley already mentioned, early in the 20th Century we wouldn't really be thinking much of cigarettes, and they were just a very peripheral sales consumer item. And over the course of the 20th Century, we came to a point in the middle of the century of the 1970s, and '80s where about half of all American adults were smoking cigarettes regularly. I wanted to understand that. How do you take something that's at the very margin of the economy and culture and make it a dominant consumer force? And I think in that way, we have certain parallels to ultra processed foods. But then there were the questions, how do you make it so popular? Is it dangerous to use? Is it addictive? Does it cause disease? And how do you resist regulation and other public health approaches to try to keep people smoking? And I found a lot of evidence in each of those areas, both of how the industry acted. And when you say, you know, it's ultra processed food like cigarettes, we're learning a lot about ultra processed foods. But we know a ton about what the industry did to make the 20th Century what I call the Cigarette Century. And we have seen really important declines in smoking in the last 30-40 years. It's a remarkable public health effort. But at the same time, the industry worked incredibly hard and, in some ways brilliantly, to maintain the popularity of their product. And underlying all this is the idea that nicotine is highly addictive. And the industry came to understand that certainly before consumers did. And as a result, they could engineer, manage, manipulate the addictive character of a product that kills. I think looking for parallels, both in terms of how the industry did it and how perhaps public health law regulation can undo it, is the critical aspect of what we've been working on together. Okay. So, the tobacco industry did more than just take a plant, dry it out, chop it up, and roll it up in some paper. Then people might be driving whatever natural pleasure there would be from that product. But they did more, didn't they? Allan - Yes. And you talked about nicotine in particular. So how manipulated was this industrial process and was it designed to create such high levels of addiction? Allan - Well, for a long time we couldn't be sure about that. And we have learned that the industry had learned sophisticated techniques of industrial production of cigarettes. So, it wasn't like just chopping up tobacco and putting it in paper. You know, they added many additives. They added liquids. They dried it out, they put it in long strips of tobacco for cutting and packaging. And they had innovated the technologies, instead of human beings rolling cigarettes, they were able through machinery and technology to produce hundreds of thousands of cigarettes a day. And then they had to figure out how do we sell this tremendous volume of cigarettes in order to make our industry truly lucrative. So, there were those aspects. And certainly by the middle of the 20th Century, many people realize that - I smoke regularly and I crave my next cigarette and I'm smoking a pack a day, sometimes two packs a day. And people would ask, well, is it a habit? Is it habituating? Is it addictive? And as the science of addiction really grew in the middle of the 20th Century, we began to realize it had all the characteristics of addiction. But we really didn't know exactly what the companies were doing. And what we did learn in the '80s and '90s is that the companies had a precise ability to manage the nicotine in their product. And they did, so that even as they put filters on and they claimed they had safer cigarettes, they were also producing increasingly addictive cigarettes where we have craving, we have withdrawal, we have tolerance. The basic categories, that structure, how we understand addiction. Okay. We'll dive into some of those in a little more detail, but thanks for that background. Ashley, people kind of get it that drugs can be addictive and they know that alcohol can be addictive. They know that cigarettes can. But what about food? Ashley - Yes, so I think one of the things that when I take a step back, is that the reward and motivation system that alcoholic beverages, cigarettes can start to hijack and drive towards compulsive problematic use, that was laid down in the brain to make sure we were getting enough food. It's really sensitive to food reward, energy density. But the thing is you actually consume nicotine probably most days. Nicotine is actually in a lot of plants like tomato and eggplant, but nobody's getting addicted to the chemical in that delivery vehicle. I would argue the same thing's happening. When we look at our research nobody's getting addicted to minimally processed foods like bananas and broccoli, and salmon filets. It's when you're able to process and titrate and hedonically engineer food reward in a way that mimics the intensity and the sensory appeal and the spikes and crashes and the craveability of something like cigarettes, that you start to see people losing control. And when I read Allan's book, my husband was watching over my shoulder. And he's like, you know, if you highlight every single sentence, it's not gonna help you because you've highlighted the whole book. And reading what Allan laid out about how each wave of cigarette addiction, it wasn't because we suddenly discovered what nicotine was, it's because the industry got better at manipulating engineering, designing, flooding the market with it. And then health washing it, so people didn't really understand what they were getting into. And to me, that is what we've done to our food supply. And the result of that has been the astronomical increases in diet related disease and health concerns. Tell us about the concept of ultra processed food and how that fits in. Ashley - Yes. Yeah, that's a great question. So, ultra processed food is a concept that actually came out at about the same time as the Yale Food Addiction Scale, that Kelly and I published together, about how to operationalize who might be showing signs of addiction and certain foods. Carlos Monteiro from Brazil was noticing that his grocery store was starting to be flooded by foods that you could not make in your home kitchen. I have exactly no idea how to make a double stuffed Oreo or a flaming hot Cheeto, or a Cherry Coca-Cola. And as these products that were industrially created with additives and flavor enhancers that are kind of biologically novel, that's when the disease risk started to go up. And so, these foods are so fundamentally changed in they're kind of most archetypal forms of things, like sodas and, you know, your sweet, savory sort of snacks, that a whole new category had to be created for them. To really distinguish them from, you know, grandma's homemade cookies or, you know, an apple or an orange. Ashley, you're brilliant at framing things. And one of the things that I learned from you a long time ago, and I've used a thousand times in discussions with people, is thinking about food, like turning the coca plant into cocaine and into crack cocaine. That if you take the coca plant into its natural form, people can live in harmony with it. You don't really have addiction. But when you process it and it becomes cocaine, then things change dramatically. And when you hyper process it, like the hyper palatable foods and the ultra processed foods, then the crack cocaine becomes incredibly addictive. So that same sort of phenomenon I think applies here. And it's a very compelling way to think about this. Allan, let's get back to the addiction thing and tobacco. One of the most stunning things I remember about the tobacco history. Is the videotape of the seven tobacco company executives testifying before Congress that nicotine wasn't addictive. Swearing, you know, sworn statements about nicotine. Tell us about that and what that kind of meant in history. Allan - It's a great story and it has a kind of visual linkage to many of us who actually saw those congressional hearings. And it was a brilliant sort of performative politics, if you will. And there had been more and more knowledge that the industry was manipulating nicotine to make cigarettes that they were claiming were safer and not addictive, even more highly addictive. And David Kessler, the head of the FDA under Clinton, had really been a major player in this. And one thing I should say is we were learning more and more about the industry because people were suing them. And they would typically lose the suits, but they would get hundreds, hundreds of thousands of documents. And the industry also had whistleblowers who were coming forward and saying, of course we know it's addictive. So, Henry Waxman, a really fantastic congressman who represented consumers invited all seven of the major tobacco CEOs to a hearing on nicotine. And he went one by one - do you believe nicotine is addictive? And they would say, Congressman, I do not believe that nicotine is addictive. And it's like any great prosecutor, he had figured out how to get them essentially to perjure themselves in front of a congressional, and video news audience. And in fact, the Department of Justice considered for some time whether they should be put on trial and indicted for perjury before Congress. But it was so in congress, with what we had come to know, especially experts, but even, you know, parents and the public and citizens had come to know that it was incredibly difficult to get off of nicotine. It just didn't comport with our existing knowledge. And we're not quite to that point with ultra processed foods yet, but I think we have a good chance to get there because as we understand what they're doing better and we have a sophisticated understanding of the characteristics of addiction, that same question will be put ultimately to CEOs of the food industry. Especially those who are producing these highly addictive products. And there are many people who are involved in this. So, they will tell a story of how we understood we could make our product sell better and be used at a much higher level if we could make it addictive. And regrettably, as we learn more about addictive addiction, we not only learn perhaps how to help people who are addicted. But we often learn how to make certain products even more highly addictive. Ashley, let's take what Allan said and apply it into the food arena. So, if you think about the criteria for addiction, like Allan had mentioned: cravings, withdrawal, and tolerance, and, tolerance being the need to have more of the substance over time in, in order to produce the same pharmacologic effect. How do those things apply to foods? Ashley - Yes. There there's very strong parallels there. And I actually have a paper I wrote with Dr. Alex DiFeliceantonio, where we took the 1988 Surgeon General's report on the addictiveness of tobacco and nicotine in particular. And we took what they identified as the necessary and sufficient criteria to prove that it was addictive. It was a watershed moment for tobacco. And the major one is that people consume it compulsively. Meaning, you know, they want to cut down and they can't. They know it's harming them and they can't. Clearly we see that with ultra processed food. That it shifts mood. It increases pleasure. It reduces negative affect through its mechanism on the brain. And I think if you look at any marketing, you know, they're always saying you're craving meet your maker, get your bliss point. You're not you unless you're eating a Snickers. They show that it was highly reinforced. And that is, you know, animals and humans will work really hard to get access to it. With nicotine one of the major points of that is that animals, about 20% of the time, would work to get nicotine over cocaine. And that was quite striking because cocaine is so powerfully addictive. Well in those same models, animals will work for processed sweet taste and choose it 80% of the time over cocaine. It just shows that when we start altering, processing food reward into these unnaturally intensely stimulating packages, our brains were not evolved to protect itself against that. And then the final pieces that's been kind of added over time has been the cravings. I mean, if you think about what is the core of addiction, it's the craveability of it. That they maximize that. So, you can't stop thinking about anything else. And when I read, and we even quote in our paper, spots where, you know, industries, the big food is having webinars and how to turn cravings into corporate wins. And how to take snackers who are consuming, because their cravings feel unmanageable, but here's how you can keep them snacking even though they want to quit. And so, the craving really seems to me, based on my read of what I've seen from the industry, is the core engine of driving and selling ultra processed food. So, these foods, and I've heard you say this, Ashley, you know, they have less to do with the farm and, you know, these sort of romantic ideas of the farmer growing crops and the crops being harvested and coming to a farmer's market. These are really industrial lab-based, you know, heavy duty factory related products. And there's a real question, isn't there, about what you even should call them food. Ashley - Yes, absolutely. I actually grew up on a farm and I never ate anything that we grew on the farm because it was all due to Ag policy. Just, corn to go into high fructose corn syrup, soy to go into soybean oil. And I was surrounded by what looked like lots of food, but in reality, it was not. And some of the things that I learned in writing this paper with you all is just to what degree ultra processing allows them to even control the molecular structure and size of the different starch chemicals. That carby kind of access point in food. Allan talks in his book about how you can treat tobacco. So, you break it down and make it molecularly more bioavailable so nicotine gets more rapidly into the body. That's a huge driver of addictive potential. I found in ours that they were actually using enzymes that mimic what's in the saliva in your mouth. And hitting starches with it. Essentially you were predigesting, pre salivating, essentially the starch creating what's called a starch slurry. And that's a base of so many common ultra processed foods like cereals and savory snacks. Many of these products really have far more in common with that cigarette and have almost nothing in common, you know, with the apple or the can of beans anymore. You know, that image that you said about pre salivating food. I mean, it's in some ways as if the industry is spitting in your food to bypass your own biological mechanisms that occur when the food gets in the mouth and. People get a kind of a yuck response to that, but it deserves that kind of a response. Let's dive into the paper and talk about what you reported, Ashley. You talk a lot about the kind of processes. You just mentioned one of them, but there are a lot more. What are some of the specific techniques to food processing that surprised you when you started digging in. How did you get this information? Ashley - Yes, so one of the functions that actually didn't surprise me, but it made me look at it in new light, is the work on how we really changed the way we saw cigarettes when we realized they weren't just taking a plant and drying it and rolling it up. But that they were actually curating and titrating these just right doses of nicotine. So, you get stimulated, but not too satisfied and you don't feel overwhelmed by the amount of nicotine. When we realized that was very intentional and designed and titrated, that really changed this from a natural kind of product, it's just a plant to, oh, this is an in industry engineered product. They're controlling so much of this. We all know that they are altering the amount of sweetened refined carbohydrates and fats in our food. I mean, that's just plain knowledge. And at levels that go way beyond what exists in nature. But I think I've become very obsessed with extrusion technology. Extrusion is something where they take really high pressure, high shear mechanical impact, high pH, high temperature. And they can break the corn or the potatoes and things into this slurry that is broken down again into this kind of predigested molecular base that on its own is nasty. No one is like, oh, starch, slurry, yes! They need all the sensory and flavor additives to blitz that and texturize it so it can trick your brain into thinking it's appealing. I realized that actually has such a strong parallel to modern cigarette where, as Allan talks about in his book, one of the major technological advances was creating reconstituted tobacco where they take the tobacco scraps and they do the same sort of process to create what they call a tobacco slurry. That was then very easy to manipulate by putting flavor and preservative additives in it, and that's what makes up a large component of modern cigarette. And so, when we look at these processes and those sensory additives, the flavors, that are put in it, cigarettes have more sugar and flavor additives in them by weight than they do nicotine. And so many of those flavor additives are actually in our ultra processed food supply. Why? Because the flavor and sensory profiles are what you start to become really emotionally attached to. And that starts to drive brand loyalty from a very young age. I could go on and on and on. Oh man, we could be here for a day, so I'm really inhibiting myself. I'll be exhausted. I'll have to go get an ultra processed food from this. But it was stunning to me to see how the goals of the engineering were so shared. And I guess it shouldn't surprise us because, you know, we know that the tobacco companies like Philip Morris and RJ Reynolds actually created, manufactured and sold many of our favorite ultra processed foods that are now in our modern food supply, like Fig Newton's and you know, Hawaiian Punch and things. It really came from the same industrial practices. So Allan, I want to bring this back to the tobacco industry in a minute, but Ashley, I wanted to ask you first. I'm going to make a characterization. Tell me if I'm off on this. The industry is kind of manipulating every possible characteristic of a product. Its fragrance, its color, its texture, everything in the ways you mentioned. It becomes this industrialized product much more than a food. People consume it. They get immense reward from it because it's delivering a drug, basically, to the brain very quickly in a very efficient way. People then, of course, want more of that sensation. If tolerance exists, then it means they need more of the food over time in order to get the same reward. And then you've got a public health nightmare on your hand because people aren't just eating a little bit of these foods, they're eating a lot of these foods. And they're designed in order to produce that very impact. Does that seem fair? Ashley - Absolutely. That sums it up quite nicely. Okay, Allan, back to the tobacco experience. This kind of information that Ashley is talking about in the context of food, and you talked about in the context of tobacco. Manipulation of the product. As this kind of damning information became public knowledge, how did that happen in the tobacco arena? And then what was the consequence? Was it, you mentioned whistleblowers; was it investigative journalism? The hearings you mentioned were important. Scientific research, discovery. It sounds like a whole lot of things happened that made this information available to the public, which in turn changed public opinion against the industry. Allan - Yes, I think that's exactly right. It changed public opinion and it changed public policy and it took a long time. So, these are aspects that I think we have to, you know, acknowledge in thinking about public health and especially these powerful commercial interests that spend a lot of money on lobbying. They spend a lot of money on advertising. They know how to get to kids. These are very challenging. I do think, you know, early in the anti-tobacco campaigns, there were a few lawyers who said, well, we're going to sue them because they have misled, deceived, and in some instances probably acted criminally to build their addictive and extremely harmful life-threatening product. And people said, well, you know, it's everybody's decision whether they want to smoke and people quit all the time, so you're not going to do very well. And I think as a young academic type, I was very skeptical of the suits against the companies. But one thing that happened that I think was unanticipated, the lawyers asked for the company's records and their research reports and what people were doing. And they took depositions and the lawyers often lost the case, but they won an incredible archive that was incredibly self-incriminating of what the industry knew. When they knew it and how they continued to act to sell a harmful product. And I think that began to change things. So once you have documents, you know you're going to be more successful in court. Once you have some documents, you can call the CEOs in and say is it addictive? When they say no, you have documentation to challenge them about their own industry. Obviously, education is important. Investigative journalism. A lot of the documents not only came from the court suits, but from whistleblowers who snuck them out of law firms. Some of the whistleblowers came directly from the industry where they said, here's what my bosses told me. They need to know can you make this cigarette even more addictive? And they knew, for example, that taking nicotine out of cigarettes, which is not that difficult to do given the extent of manipulation, had to be something that was resisted. We could end the tobacco pandemic by just removing nicotine. Even if we did, you know, 10% a year. Many people would be able to stop smoking who cannot. But we had to array a kind of knowledge and practice and advocacy that really hadn't existed till the second half of the 20th Century. Ashley, when Allan mentioned these archives that exist on tobacco industry behavior, there's some food things in there, aren't there? Tell us about that connection between tobacco and food companies. Ashley - Yes, so you know, actually, Dr. Laura Schmidt at University of California - San Francisco, has done this just stunning work by using those same tobacco archives. Because they owned alcoholic beverage and ultra processed food and beverage companies she's been able to show really how much these industries kind of spoke back and forth. The different sectors of Philip Morris and RJ Reynolds, you know, they're big conglomerates. They were pulling scientists working on the cigarettes, or the marketers working on marketing cigarettes to kids, and putting them on and intentionally using that playbook to sell their ultra processed foods and beverages. That's very clear and very intentional. They might not say as blatantly. I feel like they learned their lesson a little bit. Oh, we're going to make this more addictive. They use synonyms even out in the public. Some of it that we report in this paper is not hidden. It's industry trade newsletters. It's interviews on 60 minutes with labor scientists where they're saying, yeah, we design these products, so you get a big flavor burst. And then it fades really rapidly because that makes you want to keep coming back for more and more and more. And yeah, addictive is a good word for that. And so there is this moment where it just becomes so implausible that they don't know that they have crossed the Rubicon into something that is hooking people. That plausible deniability that we're just, you know, giving consumers what they want, not actually engineering their desires to override what they know they should have to nourish themselves. It just feels beyond the pale to me to believe that's the case. Allan, look, you mentioned delay. And I'd like to talk about that a little bit more. There's a point in time when the science on something becomes robust. And you're very certain say that tobacco is causing lung cancer and heart disease.  And then you can't change things the next day or the next week. So, a little bit of delay is probably acceptable and to be understood. But the delay in this case between that knowledge and significant public health action policy action wasn't measured in days, weeks, months, or even years. It was decades. And you can count the number of attributable deaths to that delay in the millions. What did the industry do to make that delay as long as possible in terms of planting doubt, conflicts of interest with science and things like that? Allan - This is highly relevant to our moment because I make a few claims in the book. One is that the industry invented disinformation and misinformation. And there's always this way that says, well, I know that study appeared, but we need more information. And this was very clever on the part of the tobacco companies because they said, well, you know, that science shows this, but that science is unreliable. And we need to use different methods. And lung cancer is not a result of cigarette smoking, it's actually genetic. And maybe there are a few people that shouldn't be smoking cigarettes. We should be able to identify what's different about them. They kept finding strategies of delay, manipulation, building uncertainty. There's one of the tobacco documents in this phase that says, from now on, our product is doubt. And what they really needed to do to sell the product was to create doubt about a science that was highly robust and really important to consumers. On the other hand, I think consumers are sensitive to being manipulated. They don't like that. They don't like being tricked. They know these industries, especially tobacco industry, you know, is disreputable. And as that became the case, what did they know and what are they selling. We began to see some slow shifts in public awareness. And, you know, it's so interesting presenting the cigarette problem to a jury in 1970 became radically different than presenting the case against the tobacco companies in the 1990s. And a lot had changed, A lot had been documented and, you know, we never even thought of the idea that a company would scientifically mislead us probably until in any consequential way till the middle of the 20th Century. And now we're incredibly skeptical and I think taking advantage of the public skepticism, both politically and culturally is going to be one of the important issues of pushing back against what I've called rogue industries. They're operating unethically; in many cases, unlawfully. They're misrepresenting what they produce. And they have the idea that having addicted customers is the best customer. And Warren Buffet once said, you know the tobacco industry, that's crazy. It cost a dime to make it. You sell it for a dollar and its addictive. He said, what industry could be more, you know, lucrative than tobacco? Ashley, how do those things apply into the food area now? Ashley - Oh, my brain is just exploding with all the things I want to say. But I think I have an answer to Warren Buffett, which is if you've pulled all those same levers and pretend to people that it's food, and it's because we all have to eat, you know? And I walk around a grocery store and I, in my head, I'm like, if I waved a magic wand, and all the products in here that are masquerading as food but are actually ultra processed, chemically adulterated starch, slurries essentially disappeared. There is so little food in my grocery store. Real food. And it's also expensive. We would be rioting in the streets if we really saw the degree that we're not being adequately nourished or supported in our current environment. And it's the mirage of abundance that is totally hooking us. You know, taking us hook, line, and sinker. And so, you know, I'll have people often say to me, you know, it's food. Like can't really be addictive. We all need to eat. And to me that is absolutely true. Just like we all need pain management. And there used to be a belief, a myth, that if you were in pain, you couldn't get addicted to painkillers like opiates which we now know is incredibly wrong. That just because we need calories to survive doesn't mean that if you manipulate and hedonically engineer those products, that it won't impact the brain in a way that can drive it in compulsive problematic ways. It's so essential for us to carve out, yes, you need real nourishing food. This is real nourishing food and these other things. I'd love it if the grocery store, it's like you're walking around this spot, you know you're getting real food. Sure, you want to go get those Cheetos, go for it. But it's in a very clear designated area that you're not being tricked into thinking that you're eating something that's nourishing you when it's really addicting you. So, people have very strong affective attachments to foods. Particular foods that they like. Some of it is kind of what you grew up with, what your parents gave you, but a lot of it's marketing as well. And you mentioned a Cheeto or Coca-Cola, or a Dorito or a Twinkie or whatever it is. People don't want that taken away from them. Tell me if this is correct, the problem isn't so much that people eat Cheetos. It's that they overeat Cheetos, and then you add to that all the other thing, not just that food. But then you've got a real problem. Could it be a matter of just removing some of the especially troublesome ingredients from that. If you look at the list of ingredients on these foods, there could be 25 or 30 different ingredients. Well, what if, what if 12 of them got taken out or 13 or 15 of them got taken out? You'd still have the food; it would still have its taste. People could enjoy it, but it's not hijacking your biology. Ashley - Yes, I'm very skeptical of that as the response, because as Allan lays out in his book, we were like, okay, if we just get the tar out of the cigarette. You know, it's all fine, Vapes, right? Oh, you're vaping. It's fine. It will be harmless because our reward system is so porous to different levers that signal food reward. We see it with the non-sugar sweeteners. Look, we took all the sugar out, we gave you Diet Coke, we gave you non-sugar sweeteners. It's a get out of jail free card. And now we're realizing how much that messes up our gut microbiome, could potentially lead to earlier brain aging and so, you know, abstinence, clearly making this stuff illegal, that's never the goal. But I think that sense of saying, oh, we can just engineer our way out of this is unlikely. And we have the alternative. You know, for what should be the majority of what we're eating. I love a Reese's Cup, right? I will have an ultra processed food, but it shouldn't be 60% of the food supply, or 70% of what my kids are getting for their calories. And so again, that clear understanding that this is something that's fundamentally different from the food that nourishes us. We have the answer which is real food. If we poured even a tiny amount of the investment, even closing the tax loopholes on things like ultra processed food marketing to kids that they get tax breaks on and invested that into technology to make real food in its original food matrix affordable, accessible, convenient. That stuff is tasty. Have a fresh apple. It's just everything's been wired for that to be the minority of our food supply. That's often unaffordable and we all feel really time poor. These are solvable problems. We've just been shoving all our money towards how we make new flavor additives to sell high fructose corn syrup, starch, slurries. So, we just need to have the right in incentives in mind. Your point is very well taken that government trying to say, okay, let take out this ingredient or that ingredient is stepping into a trap. It makes all the sense to me in the world that that is a trap because. Using that philosophy requires a trust in the industry that if you ask them to take out these 12 things, they're not going to put in 12 new things that might even make things worse. And both of these industries, tobacco and the food industry have done everything but earn our trust so that's a very good cautionary note that you raised. I would say in the tobacco area, the idea of that we think that, you know, vaping will be harm reduction. And there's been a strong political notion that we should be, you know, doing harm reduction. And of course, in many instances, harm reduction can be helpful. But I found in tobacco, that I can't trust the industry to make a harm reduction product that's not going to get kids addicted. That's going to, you know, make sure that we're not using both tobacco and nicotine in the form of vape or other products. And so while many people who I admire in the public health world have said, yes, harm reduction is the way to go. I don't think that's true with tobacco. We have a lot of children and adolescents today who are profoundly addicted to nicotine. So, this discussion has led to lots of, oh my God, kind of observations from both of you. Paints a pretty scary picture of the food supply. How much manipulation there is. And how much harm gets caused by it. I'm hoping we might end on a bit of a positive note if there is one here. I'd like to ask each of you, is there a reason to be hopeful about the future? Allan, let me start with you. You're looking in on this with a unique perspective because of your years and years of working on tobacco. As you look in on the food space and see what's happening, what do you think? Allan - Well, I tend to be an optimist. I believe public policies can make a difference. I believe the courts can be used to serve consumers who have been harmed in the market. So, I have seen those things work to a really significant degree around the cigarette. Especially in countries where we have resources for education, where we can make policies that sometimes work or mostly work. I don't think I ever would've thought when I started this work in like the 1980s that we would've gotten so far. I once said to my son when he was seven, he was taking a flight with me. And I said, you know, people used to smoke on airplanes. And he said, no, that's impossible. And he just couldn't believe the idea that we had let people smoke on airplanes. And I've been collecting cigarette packages that were given out by the big airlines. Of course, you and I, Kelly, remember probably, when they start to put smokers in the back of the plane. But the smoke was wafting throughout it. And a lot of things that seem almost impossible now, were actually reduced through regulation and politics and public health. I'm very hopeful that we can use what we've learned about how to get smoking from 50% of the population down to 15 or 12, as bad as that is. And apply it to other gigantic risks like ultra processed foods. All right, thanks for that positive note. Ashley, what do you think are there grounds for being positive? Ashley - Yes, I'm also a huge optimist. I feel wildly optimistic. I just, from listening to consumer sentiment right now, the degree to which corporations are able to hack our limbic systems, I mean, you see it right now with social media and sports betting. I think in our bones as a society, we're starting to just get fed up. And to me there is nothing that is more clear cut of how industries can manipulate us than taking food, the thing we most evolved to care about and to find rewarding and nourishing, and somehow jacking it up into an addictive, harmful substance. And I have two little kids. I have a five and 7-year-old and I am just as a mom full of rage every time I go grocery shopping because they've just shoved protein in a Pop-Tart, now they're trying to tell me it's a health food. I think we're catching onto them, and I think that there is no way to go but up. And again, we already have the solution. In opiates, we are still struggling to find non-addictive pain management. We have non-addictive food and it's called, you know, minimally processed real foods. So, it's just about putting the incentives in the right place. BIOS Ashley Gearhardt, Ph.D., is a Professor of Psychology in the Clinical Science area at the University of Michigan. She also earned her B.A. in psychology from The University of Michigan as an undergraduate. While working on her doctorate in clinical psychology at Yale University, Dr. Gearhardt became interested in the possibility that certain foods may be capable of triggering an addictive process. To explore this further, she developed the Yale Food Addiction Scale (YFAS) to operationalize addictive eating behaviors, which has been linked with more frequent binge eating episodes, an increased prevalence of obesity and patterns of neural activation implicated in other addictive behaviors. It has been cited over 800 times and translated into over ten foreign languages. Her areas of research also include investigating how food advertising activates reward systems to drive eating behavior and the development of food preferences and eating patterns in infants. She has published over 100 academic publications and her research has been featured on media outlets, such as ABC News, Good Morning America, the Today Show, the Wall Street Journal, and NPR. Allan M. Brandt is the Amalie Moses Kass Professor of the History of Medicine and Professor of the History of Science at Harvard University, where he holds a joint appointment between the Faculty of Arts and Sciences and Harvard Medical School.  Brandt served as Dean of the Graduate School of Arts and Sciences from 2008 to 2012.  He earned his undergraduate degree at Brandeis University and a Ph.D. in American History from Columbia University.  His work focuses on social and ethical aspects of health, disease, medical practices, and global health in the twentieth century.  Brandt is the author of No Magic Bullet:  A Social History of Venereal Disease in the United States since 1880 (paperback, 1987; 35th Anniversary Edition, 2020); and co-editor of Morality and Health (1997).  He has written on the social history of epidemic disease, the history of public health and health policy, and the history of human experimentation, among other topics.  His book on the social and cultural history of cigarette smoking in the U.S., The Cigarette Century: The Rise, Fall, and Deadly Persistence of the Product that Defined America, was published by Basic Books in 2007 (paperback, 2009).  It received the Bancroft Prize from Columbia University in 2008 and the Welch Medal from the American Association for the History of Medicine in 2011, among other awards.   Brandt has been elected to the National Academy of Medicine and the American Academy of Arts and Sciences.  In 2015, he was awarded the Everett Mendelsohn Excellence in Mentoring Award by the Harvard Graduate School of Arts and Sciences.  In 2019-20, Brandt was a recipient of fellowships from the American Council of Learned Societies and the Radcliffe Institute for Advanced Study.  He recently served as the interim chair of the Department of Global Health and Social Medicine at Harvard Medical School.  Brandt is currently writing about the history and ethics of stigma and its impact on patients and health outcomes.  

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comThis week on the podcast, Mikki speaks to Dr. Eric Ravussin, one of the world's leading researchers in human metabolism, obesity, and energy balance. Over several decades, Dr. Ravussin's work has helped reshape how scientists think about body weight regulation, moving the conversation beyond the simplistic idea of “calories in versus calories out” to a deeper understanding of the biology that governs appetite, energy expenditure, and fat storage.In this conversation, Mikki and Eric explore the brain's role in regulating body weight, the influence of genetics and environment, and what his landmark research — including work with the Pima population and the CALERIE trial — has revealed about metabolic adaptation, calorie restriction, and longevity. They also discuss spontaneous physical activity, the concept of a body-weight “settling point,” and the emerging role of GLP-1 medications in obesity treatment. It's a fascinating look at the physiology of weight regulation and why maintaining weight loss is often far more complex than most people realise.About Dr. Eric RavussinDr. Eric Ravussin is an internationally recognised researcher in metabolism, obesity, and energy balance. He is Associate Executive Director for Clinical Science at the Pennington Biomedical Research Center at Louisiana State University, one of the world's leading institutions for metabolic research.For more than three decades, Dr. Ravussin's work has focused on understanding the biological drivers of obesity and weight regulation, including energy expenditure, metabolic adaptation, appetite regulation, and the role of genetics in body weight. His research with the Pima population helped illuminate the powerful interaction between genetics and environment in the development of obesity.Dr. Ravussin has also been a principal investigator in the landmark CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial, the first long-term randomised controlled trial examining the physiological effects of sustained calorie restriction in humans, including its potential implications for metabolic health and longevity.He has authored hundreds of scientific publications and remains a leading voice in research exploring how biology, behaviour, and environment interact to shape body weight and metabolic health.Prof Ravussin's faculty profile:https://www.pbrc.edu/research-and-faculty/faculty/Ravussin-Eric-PhD.aspx  Curranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzContact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Drs Kaniksha Desai and Juan Camacho discuss thyroid artery embolization. This podcast is intended for healthcare professionals only. Kaniksha Desai, MD, Associate Professor of Medicine, Department of Endocrinology, Stanford School of Medicine, Palo Alto, California Juan C. Camacho, MD, Clinical Associate Professor, Vascular & Interventional Radiologist, Department of Clinical Sciences, Florida State University, Sarasota Memorial Hospital, Sarasota, Florida To read a transcript or to comment, visit https://www.medscape.com/index/list_15483_0

What happens when the sport you've dedicated your life to suddenly gets taken away from you?At 17, Nina Derron was a Swiss Junior Champion in triathlon, duathlon, and the 10km. And then chronic back pain stopped everything...What followed was nearly 3 years away from competition, a PhD in Clinical Science from ETH Zurich, and one of the most remarkable comeback stories in triathlon.In this episode, Nina walks us through the injury that derailed her junior career, how she rebuilt her relationship with the sport, and the deliberate decision, at 32, to finally go all-in as a full-time professional triathlete. We also dive into Brett Sutton's RPE-based training philosophy, why Nina barely looks at her data, what it's like training alongside the Chinese national team, and the importance of bone density screening for young endurance athletes.A story about patience, resilience, and trusting the process: for athletes and coaches at every level.--Connect with Nina: @nina_derronConnect with Bruna: @justbrunathingsConnect with Fabi: @endurance_fabiSign-up for augo's launch event: https://luma.com/8l4kbup7

In this episode, we are honored to welcome Dr. John Z. Sadler, one of the most influential figures at the intersection of psychiatry, ethics, and philosophy. For more than four decades, Dr. Sadler has shaped the intellectual and moral foundations of psychiatric diagnosis, values-based practice, and clinical ethics consultation.Dr. Sadler is the Daniel W. Foster, MD Professor of Medical Ethics and Professor of Psychiatry and Clinical Sciences at UT Southwestern Medical Center, where he directs the Program in Ethics in Science & Medicine and leads the Division of Ethics in the Department of Psychiatry. He has served on the Parkland Hospital Ethics Committee since 1985 and was its co-chair and clinical ethics consultant for three decades—bringing philosophical inquiry directly into the realities of patient care.A co-founder of the Association for the Advancement of Philosophy and Psychiatry and longtime co-editor of Philosophy, Psychiatry, & Psychology, Dr. Sadler has helped define an entire field of scholarship. He is the author of Values and Psychiatric Diagnosis and the recently published Vice and Psychiatric Diagnosis, co-author of The Virtuous Psychiatrist, and editor of multiple definitive reference works including the Oxford Handbook of Philosophy and Psychiatry, the Oxford Handbook of Psychiatric Ethics, and the Oxford Handbook of Psychotherapy Ethics.In this wide-ranging conversation, we explore why philosophy matters in everyday psychiatric practice, from how values shape diagnostic systems like the DSM and ICD, to the ethical tensions that arise in clinical care. Dr. Sadler reflects on the virtues essential to modern psychiatrists, how trainees can cultivate conceptual competence, and where the philosophy of psychiatry is headed globally. The result is both an intellectual masterclass and a thoughtful meditation on what psychiatry is, and what it ought to be.Music from #Uppbeat (free for Creators!):https://uppbeat.io/t/cruen/city-streetsLicense code: 2JJVCBQKEE2GJH5N

In this episode, Annika Theodoulou speaks to Professor Jonathan Bricker, a Professor of Public Health at the Fred Hutchinson Cancer Research Center and Affiliate Professor of Psychiatry at the University of Washington in Seattle, Washington, US. The interview covers Jonathan's research article covering intersectionality in cigarette smoking cessation using a latent class analysis to predict 12-month cessation in a randomized controlled trial.Intersectionality and why it is important to explore in smoking cessation [01:19]Six factors that are well-known predictors of smoking [03:20]The aim of a latent class analysis [04:55]The key findings of the study [07:09]The differences found between smartphone apps used in the trial [11:02]The implications of the findings for policy and practice [14:49]About Annika Theodoulou: Annika is a researcher at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. Her work focuses on health behaviours, including smoking cessation and weight management, with an emphasis on evidence synthesis. Annika's doctoral research, funded by the Society for the Study of Addiction (SSA) and The Rotary Foundation, examined socioeconomic inequalities in smoking cessation behaviours and outcomes using quantitative and qualitative methods. She is an Associate Editor of Nicotine & Tobacco Research. Annika holds a Bachelor of Health Sciences and a Master of Clinical Science from the University of Adelaide.About Jonathan Bricker: Jonathan is an expert in the field of health behavior change interventions. He is a Full Professor of Public Health at the Fred Hutchinson Cancer Research Center and Affiliate Professor of Psychiatry at the University of Washington in Seattle, Washington. Dr. Bricker is founder and leader of the Health and Behavioral Innovations in Technology (“HABIT”) Research Group. The HABIT research group focuses on developing and testing innovative theory-based behavioral interventions for tobacco cessation and weight loss, especially those delivered in widely disseminable technology platforms. He and his team have developed a novel health behavior change intervention model based on the principles of Acceptance and Commitment Therapy (“ACT”). The principal investigator of over $35 million US dollars in research grants, he has been leading ten NIH R01 randomized trial grants, as well as led or collaborated on multiple other Federal and private research grants. His current grants focus on testing a machine learning natural language processing chatbot for quitting smoking, several smartphone applications for tobacco cessation in the general population, among cancer patients, American Indians & Alaska Natives, Hispanics, and adolescents, and a weight loss telephone coaching program based on ACT. His “iCanQuit” smartphone app based on ACT was proven more effective than a leading National Cancer Institute smartphone app based on the US Clinical Practice Guidelines in a large, randomized trial published in JAMA Internal Medicine. iCanQuit is now publicly available. He has published over 150 peer-reviewed research articles on addictions, behavioral interventions, and technologies. Currently, he serves as a Senior Editor of the journal Addiction. Original article: Intersectionality in cigarette smoking cessation: A latent class analysis to predict 12-month cessation in a randomized controlled trial https://doi.org/10.1111/add.70185Digital Object Identifier (DOI)The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Today's tip features Horses in the Morning co-hosts Glenn & Jamie along with their guest Dr. Anna Bracken chatting about winter horse nutrition.Host: Coach JennTodays contributors: Horses In The Morning, Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversityAdvertise on Horse Radio Network podcastsAdditional support for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network

Today's tip features Horses in the Morning co-hosts Glenn & Jamie along with their guest Dr. Anna Bracken chatting about winter horse nutrition.Host: Coach JennTodays contributors: Horses In The Morning, Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversityAdvertise on Horse Radio Network podcastsAdditional support for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 19 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:David Liu - Professor of the Natural Sciences at Harvard University, specialising in Molecular Biology and Organic ChemistrySteven Pinker - The Johnstone Family Professor of Psychology at Harvard University, Mark Zuckerberg = Founder and CEO of Facebook.Frances Balkwill = Professor of Cancer Biology at Queen Mary College Hospital Doctor Alexandra Solomon - Clinical psychologist, and Associate Professor at Northwestern University Dr Ed Robinson - Specialist in Cosmetic Aesthetics, and Associate member of the British College of Aesthetic Medicine Stephen Childs - Lab Technician and Analyst at Sunderland UniversityKerry Nicol - External Affairs Manager for the Chartered Trading Standards Institute Joe Morse = Associate Test Pilot for US Company Pivotal Ken Clarkin - CEO of Pivotal Dr Randy Bateman - Professor of Neurology at Washington University Dr Christos Pliatsikas -Associate Professor at the School of Psychology and Clinical Sciences at the University of Reading Paulina Arce - Veterinary expert, specialising in the Humboldt Penguin Guillermo Cubillos - Marine Biologist at Chile's National ZooContact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk Presented by Ciara Revins, written by Liam Thompson, researched by Lucie Lewis and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

In today's tip we join Horses In The Morning co-hosts Glenn & Jamie as they chat with Dr. Anna Bracken horse nutrition for winter.Host: Coach JennTodays contributors: Horses In The Morning podcast, Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversitySupport provided by Equestrian PlusAdditional support for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network

In today's tip we join Horses In The Morning co-hosts Glenn & Jamie as they chat with Dr. Anna Bracken horse nutrition for winter.Host: Coach JennTodays contributors: Horses In The Morning podcast, Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversitySupport provided by Equestrian PlusAdditional support for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network

Regenerative aesthetics continues to evolve—and polynucleotides are taking center stage. These powerful bioactive molecules are changing the game when it comes to collagen stimulation, skin healing, and true rejuvenation.

Dr. Anna Bracken joins us to talk about nutrition for winter for horses and the changes we should be making. Then the amazing artist Larissa Ann talks about the amazing art she does on saddles and some mighty weird news. Listen in…HORSES IN THE MORNING Episode 3802 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekPic Credit: Larissa AnnGuest: Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversityGuest: Larissa Ann, find her work at her website.Coupon: State Line Tack - Get 25% OFF any $49 order. Enter coupon code HRN at checkout. Please note: Some products are not eligible for the add'l discount due to manufacturer restrictions. These are noted in your shopping cart.Additional support for this podcast provided by: State Line Tack, Daily Dose Equine, Equine Network and Listeners Like YouTime Stamps:02:41 - Daily Whinnies09:35 - Larissa Ann21:56 - Anna C. Bracken36:33 - Weird News

Dr. Anna Bracken joins us to talk about nutrition for winter for horses and the changes we should be making. Then the amazing artist Larissa Ann talks about the amazing art she does on saddles and some mighty weird news. Listen in…HORSES IN THE MORNING Episode 3802 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekPic Credit: Larissa AnnGuest: Anna C. Bracken, DVM, MS, Clinical Instructor, Equine Field Service in the Department of Clinical Sciences at the College of Veterinary Medicine and Biomedical Sciences at Colorado State UniversityGuest: Larissa Ann, find her work at her website.Coupon: State Line Tack - Get 25% OFF any $49 order. Enter coupon code HRN at checkout. Please note: Some products are not eligible for the add'l discount due to manufacturer restrictions. These are noted in your shopping cart.Additional support for this podcast provided by: State Line Tack, Daily Dose Equine, Equine Network and Listeners Like YouTime Stamps:02:41 - Daily Whinnies09:35 - Larissa Ann21:56 - Anna C. Bracken36:33 - Weird News

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening and treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O., Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082  

Joe sits down with Julpohng “JP” Vilai, MD, Pediatrics Clerkship Director andAssistant Professor in the Department of Clinical Sciences at RosemanUniversity College of Medicine to talk about his journey into medicine and hisdeep commitment to community health in his hometown of Las Vegas. As VicePresident of the Nevada Chapter of the American Academy of Pediatrics and amember of the Gold Humanism Honor Society, Dr. Vilai shares how value-basedcare, humanism, and mentorship shape his work. He discusses hisleadership role at Roseman Medical Group, providing care to the underservedyouth at the Shannon West Homeless Youth Center, and his passion foradolescent, LGBTQIA+, and behavioral health. They also discuss theRoadrunner Visits and his dedication to training future physicians throughcompassionate, community-driven care.

In this episode Dr. Anthony Avellino and I discuss the following points surrounding transitions in life:Performance living:  Performance = skill minus interferenceRefirement zone vs retirement:  what is your purpose?  What brings you joy?Transitions cause stress (from high school to college to job to …)Stress = pushing past one's perceived limits and then allowing for recoveryStress, anxiety, depression, sleep difficulties, debt => impediments to successExpectations to perform, be perfect, be tough…Social media and perfect life…Keep climbing the ladder (each rung closer to success)…Resilience and Well-BeingResilience = acquired ability to recover, adapt, and grow from stressResiliency and well-being by managing stress with coping and self-care skills?Time managementHealthy sleep, eating, exercise habitsLearning opportunities to build resilience…Building blocks to success => Turn obstacles into opportunities…Kindness, compassion, love, and respect (for yourself and others) => healthy relationships“You are powerful.  Being empathetic, compassionate, grateful, caring, and kind are human being's greatest strengths.”Wonder Drug (Drs. Trzeciak & Mazzarelli):  7 scientifically proven ways that serving others is the best medicine for yourself!!Start Small:  16 minutes Rx; give, help, care, and connect more; kind acts, compassion, and selfless service for othersBe Thankful: write/send thank you notes as appreciationBe Purposeful: being part of something larger than yourself that can make a difference for others; what can I do to make your day a little better?Find Common Ground: children, sunset, cry, etcSee It: see it to feel itElevate: gravitate toward people who do kind things for others and are happy about it, and you'll boost your own happinessKnow Your Power: using your time, talent, and treasure to serve others; strengthen relationships; decrease chronic stress and systemic inflammation and boost immune system; hope matters and belief in recovery mattersAnthony M. Avellino, MD, MBAChief Medical Officer | HonorHealth Medical Group, Specialty CareAssociate Dean for Clinical Faculty Affairs, Chair of Department of Clinical Sciences, and Professor of Medicine, Arizona State University School of Medicine and Advanced Medical Engineeringfindingpurposeavellino@gmail.comThank you to Brock Fletcher and the selling team of Keller Williams Realty for their continued support of our programming!'The Tom Matt Show' Heard on-The Michigan Talk NetworkWKAR Michigan State Universities AM 870 & 102.3 FMWJIM-AM 1240 LansingWYPV FM 94.5 Mackinac Citywww.tommattshow.com(podcasts)iTunesFor more information on past guests, Tom's published books, and how to get in touch, please visit our newly updated website at https://www.tommattshow.com#RFZ #radio #broadcasting #podcast #michiganradio #lansing #michiganradio #mab #refirementzone #successstory #humaninterestpodcast #selfhelppodcast

In this episode, we give a wrap-up of late-breaking clinical science presented at the ESC Congress 2025 in Madrid. First, David Berg presents the DAPA ACT HF-TIMI 68 trial, reporting on dapagliflozin in patients hospitalized for acute heart failure, along with a meta-analysis of SGLT2 inhibitors in this setting. Next, Javed Butler highlights results of the VICTOR trial, a large phase 3 study of vericiguat in chronic heart failure with reduced ejection fraction. Then, Andre Zimerman discusses the PhysioSync-HF trial, comparing conduction system pacing with biventricular resynchronization therapy in patients with HFrEF. Finally, Kieran Docherty shares insights from a community-based study on the benefits of early initiation of disease-modifying therapy in suspected heart failure.   Additional information: Topic 1: With Gregorio Tersalvi, Mayo Clinic, Rochester, MN - USA, David Berg, Brigham and Women's Hospital, Boston - USA and Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia Results paper: Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure Replay ESC Congress Hot Line: https://esc365.escardio.org/presentation/312142 Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076575.    Topic 2: With Javed Butler, Baylor Scott & White Health, Dallas - USA and Henrike Arfsten, Medical University of Vienna, Vienna - Austria Results papers: Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial Lancet. 2025 Replay ESC Congress hotline: https://esc365.escardio.org/presentation/312148 doi: 10.1016/S0140-6736(25)01665-4.  Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682-4.   Topic 3: With Andre Zimerman, Hospital Moinhos De Vento, Porto Alegre - Brazil and Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany Methods paper: Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial Am Heart J. 2025 Dec:290:38-45. Replay ESC Congress: https://esc365.escardio.org/session/50327 doi: 10.1016/j.ahj.2025.06.002.   Topic 3: With Kieran Docherty, University of Glasgow, Glasgow - UK and Jolie Bruno, Inserm UMR-S942, Paris - France Results paper: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure Eur Heart J. 2025 Aug 29:ehaf675. doi: 10.1093/eurheartj/ehaf675.    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor. 

On this edition, Dr Kerri Gillespie from Queensland University of Technology’s School of Clinical Sciences discusses how your dinner might shape your mood. She breaks down new research from the Translational Research Institute in Brisbane showing the links between veggies, sugar, and fibre—and your mental health—and identifies some changes worth trying in what you eat.See omnystudio.com/listener for privacy information.

Did you know that the questions we ask children should change as they develop? Asking the right questions at the right time helps children's communication flourish.Paula LaSala-Filangeri is a Speech-Language Pathologist who has been supporting children and families for over 25 years.How can parents move beyond flashcards and start turning everyday routines, like walking in nature or baking a cake, into powerful opportunities for language growth?Here are a few of the key insights we'll explore:

In today's episode, we had the pleasure of speaking with Balazs Halmos, MD, MS, about the phase 2 VISION trial (NCT02864992) evaluating tepotinib (Tepmetko) in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). Dr Halmos is a professor in the Department of Oncology (Medical Oncology) and the Department of Medicine (Oncology and Hematology), director of Thoracic Oncology, and associate director of Clinical Science at Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. In our exclusive interview, Halmos discussed the rationale and design of the VISION trial, the significance of MET exon 14 skipping mutations as a distinct oncogenic driver, and the clinical utility of tepotinib, which is a selective MET TKI. He reviewed the trial's efficacy results, which demonstrated consistent response rates across lines of therapy and diagnostic methods, as well as tolerability findings that highlighted the importance of monitoring and managing MET-related adverse effects. Dr Halmos also reflected on subgroup analyses from the trial, noting the agent's activity across treatment settings, particularly in older patients and those with central nervous system involvement. Additionally, Halmos underscored the critical role of comprehensive biomarker testing in NSCLC, highlighting how parallel tissue- and circulating tumor DNA–based testing can optimize timely identification of actionable alterations and ensure patients receive the most effective frontline therapy. He also discussed practical considerations for dose selection and modifications with tepotinib, offering insights into strategies for maximizing treatment benefit and maintaining patient quality of life.

Motherhood takes it out of you. Physically. Mentally. Emotionally. And if you've ever felt like your energy's been zapped or your brain's running on 1%, you're not imagining it and you're definitely not alone.In this episode, Dr Renee White takes you on a deep dive into a surprising topic: creatine supplementation for women's health. That little white powder you've seen on gym shelves? It turns out, it might hold more benefits for mums than we ever realised.From brain fog and bloating to sleep, strength and recovery, Renee unpacks the latest research on how this naturally occurring compound can support women through every life stage. With her signature mix of science and soul, she breaks it down in a way that's easy to understand and incredibly relevant for busy, brilliant mums like you.You'll hear about:

Join ETSU Provost Dr. Kimberly D. McCorkle in this inspiring episode of the “Why I Teach” podcast as she speaks with Dr. Kyle Leister, Assistant Professor and Program Director of ETSU's new Master of Science in Orthotics and Prosthetics program – the first in Tennessee and one of only 14 nationwide. Dr. Leister shares his unique journey into rehabilitative medicine – from treating NHL athletes with the Pittsburgh Penguins to working on Paramount Studios' medical team – as well as his passion for student mentorship and the human side of prosthetic and orthotic care. Listen to more episodes of “Why I Teach,” where Dr. Kimberly D. McCorkle explores stories of impact and success of ETSU faculty. Subscribe at https://why-i-teach-conversation-with-etsu-faculty.podbean.com/. Other resources: ETSU College of Health Sciences:  https://www.etsu.edu/chs/ ETSU School of Clinical Sciences: https://www.etsu.edu/chs/clinical-science/default.php ETSU Master of Science in Orthotics and Prosthetics: https://www.etsu.edu/chs/rehabilitative-sciences/orthotics-prosthetics/default.php ETSU Health: www.etsuhealth.org

According to the CDC, almost 10% of American women of child bearing age are on SSRIs – Selective Serotonin Reuptake Inhibitors – a class of antidepressants that include such medications as Lexapro, Prozac and Zoloft. But are they safe to take during pregnancy? Tracy Beth Høeg, MD, PhD and Senior Advisor for Clinical Sciences in […]

In this episode, Dr. Jill is joined by Dr. Chris D'Adamo, a leading researcher in integrative health and nutritional immunology, to discuss the critical role of beta glucans in supporting and modulating the immune system.

Performance Living is our gateway to Dr Anthony Avellino.  His expert knowledge regarding technology is unparalleled.  As Associate Dean for Clinical Faculty and Chair of Clinical Sciences at Arizona State University School of Medicine and Advanced Medical Engineering Tony has a unique way of bringing complex topics to our program and, as they say in sports, "we break down the tape".  In this episode listen for-Neurosurgical advances such as AR/VR- mixed realityPatient engagementPatient educationHow artificial reality and virtual reality is now readily available for patients and doctorsFor more information on Dr. Avellino, please visit: https://www.findingpurposeavellino.com/'The Tom Matt Show' Heard on-The Michigan Talk NetworkWKAR Michigan State Universities AM 870 & 102.3 FMWJIM-AM 1240 LansingWYPV FM 94.5 Mackinac CityWGHN-92.1 FM Grand Havenwww.tommattshow.com(podcasts)iTunesFor more information on past guests, Tom's published books, and how to get in touch, please visit our newly updated website at https://www.tommattshow.com#RFZ #radio #broadcasting #podcast #lansing #michiganradio #mab #msu #mentalhealth #physicalwellness #smartliving #bodyandmind #AImedicine #AImedicaltechThank you to Brock Fletcher and the selling team of Keller Williams Realty for their continued support of our programming!'The Tom Matt Show' Heard on-The Michigan Talk NetworkWKAR Michigan State Universities AM 870 & 102.3 FMWJIM-AM 1240 LansingWYPV FM 94.5 Mackinac Citywww.tommattshow.com(podcasts)iTunesFor more information on past guests, Tom's published books, and how to get in touch, please visit our newly updated website at https://www.tommattshow.com#RFZ #radio #broadcasting #podcast #michiganradio #lansing #michiganradio #mab #refirementzone #successstory #humaninterestpodcast #selfhelppodcast

LATE BREAKING CLINICAL SCIENCE: Comprehensive Radiation Shield Minimizes Operator Radiation Exposure in Coronary and Structural Heart Procedures

In a recent episode of Oncology on the Go, several oncologists discussed the impact of the COVID-19 pandemic on oncology care, 5 years later. Each doctor discussed a different aspect of multidisciplinary care, including medical oncology, radiation oncology, and epidemiology. CancerNetwork® spoke with leading clinicians including:  ·      Aditya Bardia, MD, MPH, FSCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center; ·      Ritu Salani, MD, director of Gynecologic Oncology at the University of California Los Angeles, and ONCOLOGY® editorial advisory board member; ·      Scarlett Lin Gomez, PhD, MPH, a professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF), and co-leader of the Cancer Control Program at UCSF Helen Diller Family Comprehensive Cancer Center ·      Marwan F. Fakih, MD, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center; ·      Elizabeth Zhang-Velten, MD, a radiation oncologist at Keck Medicine of University of Southern California;  ·      Frances Elain Chow, MD, neuro-oncologist at the University of Southern California (USC) Norris Comprehensive Cancer Center ·      James Yu, MD, MHS, FASTRO, assistant professor adjunct, Department of Radiation Oncology, Smilow Cancer Hospital at Saint Francis Hospital, and ONCOLOGY® editorial advisory board member.  The COVID-19 pandemic disrupted routine cancer care in a number of ways. Many patients were unable to receive timely screening, diagnosis, and treatment, Fakih noted. Additionally, Bardia stated that the pandemic led to a decrease in the number of patients participating in clinical trials. One of the most significant changes in oncology care, according to Salani, has been the increased use of telehealth. Telehealth has allowed patients to receive care from the comfort of their own homes, which has been especially beneficial for patients who live in rural areas or who have difficulty traveling. Telehealth has also made it easier for patients to connect with their doctors and to receive support from other members of their care team.  For Gomez, the COVID-19 pandemic also highlighted the importance of addressing the structural and social drivers of health. These are the conditions in which people are born, grow, live, work, and age that can affect their health. For example, people who live in poverty or who lack access to healthy food are more likely to develop cancer. The pandemic has led to a renewed focus on addressing these disparities. Overall, the COVID-19 pandemic has had a profound impact on oncology care. However, it has also led to a number of positive changes, such as the increased use of telehealth and the focus on addressing the structural and social drivers of health. In the years to come, it will be important to continue to build on these changes in order to improve the lives of patients with cancer.

LATE BREAKING CLINICAL SCIENCE: CT-Guided Ozone-Mediated Renal Denervation Treating Resistant Hypertension

LATE BREAKING CLINICAL SCIENCE: Benefits of Dynamx Bioadaptor Versus DES in Patients With Dyslipidemia: Subgroup Analysis Results from the BIOADAPTOR RCT

Dr. David Brady is the Chief Medical Officer for Designs for Health, Inc. and Diagnostic Solutions Labs, LLC and an expert consultant for nutritional supplements and clinical laboratory industries. He has over 30 years of experience as an integrative practitioner and more than 25 years in health sciences academia. He is a licensed naturopathic medical physician in Connecticut and Vermont; he is board certified in functional medicine and clinical nutrition; and he is a Fellow of the American College of Nutrition. He held the long-time position as Vice President for Health Sciences and Director of the Human Nutrition Institute at the University of Bridgeport in Connecticut, where he continues to serve as an Associate Professor of Clinical Sciences, and he maintains a private practice, Whole Body Medicine, in Fairfield, CT, USA. Dr. Brady has returned to the podcast for a discussion about fibromyalgia and offers a variety of clinical pearls throughout our conversation. He highlights the differentiating features between fibro and pseudo-fibromyalgia, explains the evolution of our understanding of fibro diagnostic markers and subsequent treatments, and details the environmental triggers, predisposition and trauma that tend to lead to the onset of fibromyalgia. He also offers potential solutions that utilize supplements for mitochondrial support and deficiencies and offers an update on long COVID and increased autoimmunity in the population at large. I'm your host, Evelyne Lambrecht, thank you for designing a well world with us.   Episode Resources: Dr. David Brady - https://dss.designsforhealth.com/blogs/faculty-member/david-m-brady Design for Health Resources: Designs for Health - https://www.designsforhealth.com/ Designs for Health Practitioner Exclusive Drug Nutrient Depletion and Interaction Checker - https://www.designsforhealth.com/drug-nutrient-interaction/ Visit the Designs for Health Research and Education Library which houses medical journals, protocols, webinars, and our blog. https://www.designsforhealth.com/research-and-education/education The Designs for Health Podcast is produced in partnership with Podfly Productions. Chapters: 00:00 Intro. 01:50 Dr. Brady is looking forward to the future of Designs for Health. 3:00 A definition of fibromyalgia and the parts of the body that are widely affected by it. 7:33 Differentiating features between fibro and pseudo-fibromyalgia. 9:32 The evolution of our understanding of fibro diagnostic markers and subsequent treatments. 15:25 Common nervous system set up that leads to fibromyalgia later in life. 18:25 Findings and actions resulting from cytokine testing, heightened neural inflammation, and glial cell activation. 23:00 Updates on the link between fibromyalgia and long-haul COVID 19. 26:14 The use of 5-HTP in regulating limbic system dysfunction, neurotransmitters and heightened pain receptors. 31:55 Utilizing botanicals in calming adaptogens and those that are not stimulating. 33:05 5-HTP use for those with SNPs in MAO-A or -B for brain retraining in calming and relaxation. 36:36 Fibromyalgia pain is presented in constant and regular symptomatology. 38:45 Environmental triggers that bring on fibromyalgia, in addition to the intersection of predisposition and trauma. 44:06 Gender and hormonal differences in the onset and presentation of fibromyalgia. 45:50 Potential solutions that utilize supplements for mitochondrial support and deficiencies.  51:56 Managing inflammatory and joint pain in fibromyalgia. 54:42 Dietary patterns and food sensitivities that are common in patients with fibromyalgia. 56:48 Peptide therapy options for patients with fibromyalgia. 59:29 An update on long Covid and increased autoimmunity in the population at large. 1:02:48 Dr. Brady's latest intrigue supplements, current health practices, and the need to be right all of the time that he has changed his mind about.

LATE BREAKING CLINICAL SCIENCE: AltaValve Atrial Fixation TMVR Early Feasibility Study Results

Praveen Kumar, Director and Heard of Clinical Sciences at nference, a physician, clinical pharmacologist and an advocate for real-world data in drug development and medical devices. Praveen is passionate about leveraging AI, machine learning and data-driven insights to optimize clinical trials, reduce development costs and improve patient outcomes In this episode, we explore the critical role of real-world data in shaping the future of medicine, how it differs from traditional clinical trials and why it's increasingly being used for regulatory approvals. Praveen shares real-world case studies of drugs and devices that have successfully used real-world data, the challenges in global regulatory acceptance and how AI is transforming patient recruitment and trial efficiency Timestamps: [00:00:27] What is Real-World Data? [00:02:30] The Key Differences Between Clinical Trials and Real-World Data [00:06:46] How Real-World Data is Used for Drug Approvals [00:08:28] Cutting Drug Development Costs with AI [00:15:33] The Growing Role of Drug-Device Combinations [00:21:53] Emerging Trends in AI and Real-World Evidence [00:25:38] Challenges in Global Regulatory Acceptance Get in touch with Praveen Kumar - https://www.linkedin.com/in/praveen-kumar-m-33a6bab3/ https://nference.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwal Subscribe to the Podcast

Dr. Leslie Ellis is a leading expert in the use of somatic approaches in psychotherapy, in particular for working with dreams, nightmares and the effects of trauma. She is the author of A Clinician's Guide to Dream Therapy (Routledge, 2019) and offers many training opportunities in embodied, experiential dreamwork based on her book.Dr. Ailey Jolie holds a Master of Counselling Psychology and a Master of Arts in Depth Psychology with an Emphasis in Somatic Studies, and is a graduate of Harvard Medical School's Global Mental Health: Trauma Recovery Masters certificate program. Ailey also possesses two Honours Bachelor Degrees in Women's Studies, Communication and Psychology from the University of Ottawa (Université d'Ottawa). She has completed postgraduate training in Sex Therapy from Guelph University, a certificate in Sex Therapy from the Modern Sex Therapy Institute (online), Perinatal Psychology from Postpartum Support International and training in the Clinical Science of Eating Disorders from the University College London Faculty of Medicine.In This EpisodeLeslie's websiteAiley's website---If you'd like to support The Trauma Therapist Podcast and the work I do you can do that here with a monthly donation of $5, $7, or $10: Donate to The Trauma Therapist Podcast.Click here to join my email list and receive podcast updates and other news.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-trauma-therapist--5739761/support.

In today's episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Susan M. O'Brien, MD, about key data updates with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Dr O'Brien is the associate director for Clinical Science at the Chao Family Comprehensive Cancer Center, the medical director of the Sue & Ralph Stern Center for Clinical Trials & Research, and a professor of medicine in the Division of Hematology/Oncology in the University of California Irvine School of Medicine. In our exclusive interview, Drs Danilov and O'Brien discussed potentially practice-changing data with acalabrutinib (Calquence)–based regimens from the phase 3 AMPLIFY trial (NCT03836261) in CLL, key updates with zanubrutinib (Brukinsa) as monotherapy and in combination with sonrotoclax (BGB-11417) in patients with this disease, and practice-confirming findings with pirtobrutinib (Jaypirca) from the phase 3 BRUIN CLL-321 trial (NCT04666038) in patients with previously treated CLL.

Everyone who has a foot in the world of psychiatric diagnosis seems to agree that our diagnostic system could, at the very least, use some updating, if not burning it down and starting over.So how do we approach developing constructs of psychiatric diagnoses that are more complex, more accurate, more flexible, and more context-specific than what we've been taught or what exists in the DSM-V?Today, I'm excited to share my conversation with Dr. Miri Forbes, an expert in psychopathology and one of the authors of the paper, “Reconstructing Psychopathology: A Data-Driven Reorganization of the Symptoms in the Diagnostic and Statistical Manual of Mental Disorders.” Dr. Forbes and her colleagues are doing innovative research on creating more empirically-supported diagnostic constructs. This approach to symptoms, categorization, and how we think about and use diagnostic constructs is one that I hope will help us get out of the habit of taking our current diagnostic constructs too literally.Dr. Forbes, an Associate Professor at Macquarie University's School of Psychological Sciences, is focused on improving our understanding of the empirical structure of psychopathology based on the specific patterns in which symptoms of mental disorders tend to co-occur.She is an Associate Editor of The Journal of Psychopathology and Clinical Science,and serves on the Editorial Boards of Clinical Psychological Science and The Journal of Emotion and Psychopathology. Additionally, Dr. Forbes is a member of the Executive Board of the international Hierarchical Taxonomy of Psychopathology (HiTOP) Consortium.Listen to the full episode to hear:How a dimensional model can potentially help decrease stigmatizing and pathologizing of individual human experiencesHow the regrouping of symptoms creates potential for more fruitful research into how and why symptoms cluster and how best to treat themWhy reliance on current categorization and diagnostic criteria can cause clinicians to miss or lose vital information about clientsReckoning with the utility of existing diagnoses like BPD that may lack statistical supportLearn more about Dr. Miri Forbes:WebsiteTwitter: @MiriForbesLearn more about Riva Stoudt:Into the Woods CounselingThe Kiln SchoolInstagram: @atherapistcantsaythatResources:Reconstructing Psychopathology: A data-driven reorganization of the symptoms in the Diagnostic and Statistical Manual of Mental Disorders

GUEST 1 OVERVIEW: Bernie Finn is Family First's Victorian Lead Senate Candidate. A political veteran, he was the most vocal conservative member in the Victorian Parliament since first taking office in 1992. Bernie was a beacon for traditional Liberal Party values which the current leadership had rejected. As a result of his strong stance on a number of issues, he was expelled from the parliamentary Liberal Party in 2022. https://berniefinn.com/ GUEST 2 OVERVIEW: Prof. Dominique Cadilhac is Co-director and Research Lead of the  Stroke and Ageing Group, School of Clinical Sciences at Monash University. 

When did saying "I'm so stressed" become the norm? Stress seems to be a given for anyone out there adulting so it's hard to know when it becomes a problem and what to do about it. In this episode, we talk about stress with Dr. Matt Scult, VP of Clinical Science at Scenario, licensed psychologist, and Duke alum! We discuss what stress is, when is it helpful vs. harmful, and evidence-based tips to managing stress in healthy ways. He introduces Scenario, an app that helps people prepare for the stresses of everyday life. Resources:Check out Dr. Scult on Instagram @mattscultphd and his psychotherapy private practice​Check out Scenario that has a free basic version and a paid premium version coming soon! Support the Show. If you have a loved one struggling with mental health and need support, Dr. Kibby McMahon can help. Join the waitlist or email her at kibby@kulamind.com to learn more. For more info about this podcast, check out: www.alittlehelpforourfriends.com Follow us on Instagram: @ALittleHelpForOurFriends

Getting a mental health diagnosis is a powerful thing. It can make you feel less alone, but it can also impact or alter your sense of identity. In this episode of Hold On, a live national call-in about our mental health, Anna talks to Dr. Craig Rodriguez-Seijas, Assistant Professor of Psychology in Clinical Science at the University of Michigan, about his work studying bias in mental health diagnostics, particularly among LGBTQ+ individuals, and takes listener calls about how a diagnosis has shaped their sense of identity, for better or worse. Plus, Aneri Pattani, Senior Correspondent at Kaiser Health News, explains what investments the Biden administration is making toward mental health, and how soon we might see progress.